Abivax Q1 net loss narrows to €48.5 million; operating loss widens to €56.2 million

• Abivax posted a net loss of €48.5 million for the first quarter ended March 31, 2026, narrowing from €52.4 million a year earlier.
• Operating loss widened to €56.2 million as total operating income edged up to €1.3 million.
• R&D expenses climbed to €49.5 million, while G&A costs fell to €6.3 million.
• Cash, cash equivalents and short-term investments totaled €491.6 million at March 31, 2026, with runway projected into Q4 2027.
• In Study 108, 68% (88/130) of ulcerative colitis patients were in clinical remission at week 144 following dose de-escalation to 25 mg, with ABTECT Phase 3 maintenance trial topline results expected in late Q2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abivax SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605221605PRIMZONEFULLFEED1001183634) on May 22, 2026, and is solely responsible for the information contained therein.